Clinical trial NCT04033926: A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
Official title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Polymyositis
Dermatomyositis
Keywords: Myositis
Idiopathic inflammatory myopathies
Polymyositis
Dermatomyositis
Musculoskeletal Diseases
Muscular Diseases
Lead sponsor: Kezar Life Sciences, Inc.
Sponsor class: INDUSTRY
First posted: 2019-07-26
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients with active polymyositis (PM) or dermatomyositis (DM). Patients were evaluated for eligibility during the Screening Period. Eligible patients were stratified by diagnosis of DM or PM and randomized 1:1 to Arm A or Arm B of the study.

During the 32-week treatment period, patients received study drug subcutaneously (SC) once weekly with 2 treatment periods of 16 weeks each.

This study was conducted on an outpatient basis.


Eligibility criteria: Inclusion Criteria:

1. Adult patients at least 18 years of age
2. Body Mass Index (BMI) of 18 to 40 kg/m\^2
3. Diagnosis of probable or definite DM or PM by the 2017 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria
4. Must have their data reviewed by an adjudication committee to confirm eligibility unless at least 1 of the following is present:

   1. Muscle biopsy with evidence of active myositis within the last 6 months prior to or at Screening
   2. Electromyography or magnetic resonance imaging with evidence of active myositis within the last 6 months prior to Screening
   3. A creatine kinase (CK) ≥4 × upper limit of normal (ULN).
5. Must have demonstrable muscle weakness as measured by the Manual Muscle Testing-8 muscle Groups (MMT-8) with a score ≥80/150 but ≤136/150 units and any 2 of the following:

   1. Physician Global Assessment (MDGA) visual analog scale (VAS) ≥2 cm
   2. Patient Global Assessment of Disease Activity (PtGADA) VAS ≥2 cm
   3. At least one muscle enzyme laboratory measurement ≥1.3 × ULN
   4. Myositis Disease Activity Assessment Tool (MDAAT) Extramuscular Global Activity VAS ≥1 cm.
6. Documented inadequate response OR have demonstrated documented toxicity or intolerance to prior standard of care therapies
7. Has had age-appropriate cancer screening that is up to date and negative for evidence of malignancy as per local standard of care

Exclusion Criteria:

1. Has significant muscle damage or has a muscle damage VAS score ≥5 cm on the MDI
2. Any other form of myositis or myopathy other than PM or DM
3. Any condition that precludes the ability to quantitate muscle strength
4. Has severe interstitial lung disease or has a pulmonary damage VAS score ≥5 cm on the Myositis Damage Index (MDI)
5. Presence of autoinflammatory disease
6. Use of nonpermitted medications or treatments within the specified washout periods prior to screening
7. Patient has had recent serious or ongoing infection, or risk for serious infection
8. Any of the following laboratory values at Screening:

   1. Estimated glomerular filtration rate \<45 mL/min
   2. Hemoglobin \<10 g/dL
   3. White blood cell (WBC) count \<3.0 × 10\^9/L
   4. Absolute neutrophil count (ANC) \<1.5 × 10\^9/L (1500/mm\^3)
   5. Platelet count \<100 × 10\^9/L
   6. Serum AST or serum ALT \>2.5 × ULN (unless considered consistent with muscle origin)
   7. Serum alkaline phosphatase \>2.5 × ULN
   8. Total bilirubin \>1.5 × ULN (3 × ULN for patients with documented Gilbert's syndrome)
   9. Thyroid stimulating hormone outside of the central laboratory normal range
   10. Immunoglobulin G (IgG) \<500 mg/dL.
9. Presence of New York Heart Association Class III or IV heart failure, or uncontrolled blood pressure, or prolonged QT interval
10. Major surgery within 12 weeks before Screening or planned during the study period
11. Clinical evidence of significant unstable or uncontrolled diseases
12. Any active or suspected malignancy, including myeloproliferative or lymphoproliferative disorder, or history of documented malignancy within the last 5 years before Screening or within 3 years of diagnosis of myositis, except appropriately excised and cured cervical carcinoma in situ or basal or squamous cell carcinoma of the skin

Primary outcomes:
measure: Mean Change in the Total Improvement Score (TIS) From Start to End of Zetomipzomib (KZR-616) Treatment Period
timeFrame: 16 weeks in each Treatment Period (32 weeks total)
Secondary outcomes:
measure: Proportion of Patients With TIS Response
timeFrame: 16 weeks in each Treatment Period (32 weeks total)
measure: Number of Patients Meeting the International Myositis Assessment and Clinical Studies Group (IMACS) Definition of Improvement (DOI)
timeFrame: 16 weeks in each Treatment Period (32 weeks total)
measure: Mean Percent Change From Baseline From Start to End of Treatment in the IMACS Individual CSAMs
timeFrame: 16 weeks in each Treatment Period (32 weeks total)
measure: Mean Change in CDASI From Start to End of Zetomipzomib (KZR-616) Treatment
timeFrame: 16 weeks in each Treatment Period (32 weeks total)
measure: Mean Change in PP-NRS From Start to End of Zetomipzomib (KZR-616) Treatment
timeFrame: 16 weeks in each Treatment Period (32 weeks total)
measure: PK of Zetomipzomib [KZR-616] (Cmax)
timeFrame: Up to 5 hours
measure: PK of Zetomipzomib [KZR-616] (Tmax)
timeFrame: Up to 5 hours
measure: PK of Zetomipzomib [KZR-616] (AUC)
timeFrame: Up to 5 hours
measure: PK of KZR-59587 (Cmax)
timeFrame: Up to 5 hours
measure: PK of KZR-59587 (Tmax)
timeFrame: Up to 5 hours
measure: PK of KZR-59587 (AUC)
timeFrame: Up to 5 hours
Other outcomes:
Locations:
city: Beverly Hills
country: United States
facility: KZR Research Site
state: California
city: Orange
country: United States
facility: KZR Research Site
state: California
city: Miami
country: United States
facility: KZR Research Site
state: Florida
city: Atlanta
country: United States
facility: KZR Research Site
state: Georgia
city: Kansas City
country: United States
facility: KZR Research Site
state: Kansas
city: Baltimore
country: United States
facility: KZR Research Site
state: Maryland
city: Ann Arbor
country: United States
facility: KZR Research Site
state: Michigan
city: Great Neck
country: United States
facility: KZR Research Site
state: New York
city: Duncansville
country: United States
facility: KZR Research Site
state: Pennsylvania
city: Pittsburgh
country: United States
facility: KZR Research Site
state: Pennsylvania
city: Austin
country: United States
facility: KZR Research Site
state: Texas
city: Henrico
country: United States
facility: KZR Research Site
state: Virginia
city: Prague
country: Czechia
facility: KZR Research Site
city: Göttingen
country: Germany
facility: KZR Research Site
Study officials:
affiliation: Kezar Life Sciences, Inc.
name: Kezar
role: STUDY_DIRECTOR
References: